A Study of Erdafitinib Versus Investigator Choice of Intravesical Chemotherapy in Participants Who Received Bacillus Calmette-Guérin (BCG) and Recurred With High Risk Non-Muscle-Invasive Bladder Cancer (NMIBC)
Public ClinicalTrials.gov record NCT04172675. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Randomized Phase 2 Study of Erdafitinib Versus Investigator Choice of Intravesical Chemotherapy in Subjects Who Received Bacillus Calmette-Guérin (BCG) and Recurred With High Risk Non-Muscle-Invasive Bladder Cancer (NMIBC) and FGFR Mutations or Fusions
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The purpose of this study is to evaluate recurrence-free survival (RFS) in participants treated with erdafitinib vs Investigator's Choice, for participants with high-risk non-muscle-invasive bladder cancer (NMIBC) who harbor fibroblast growth factor receptor (FGFR) mutations or fusions, and who recurred after bacillus calmette-guerin (BCG) therapy.
Study identification
- NCT ID
- NCT04172675
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 107 participants
Conditions and interventions
Conditions
Interventions
Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Feb 28, 2020 (Actual)
- Primary completion
- Jul 12, 2024 (Actual)
- Completion
- Feb 27, 2025 (Actual)
- Last update posted
- Feb 24, 2026
2020 – 2025
United States locations
- U.S. sites
- 22
- U.S. states
- 16
- U.S. cities
- 22
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Urological Associates of Southern Arizona, P.C. | Tucson | Arizona | 85741 | — |
| USC Institute of Urology | Los Angeles | California | 90033 | — |
| The Urology Center of Colorado | Denver | Colorado | 80211 | — |
| Urological Research Network | Hialeah | Florida | 33016 | — |
| Emory University Winship Cancer Institute | Atlanta | Georgia | 30322 | — |
| Northwestern University | Chicago | Illinois | 60611 | — |
| Simmons Cancer Institute | Springfield | Illinois | 62702 | — |
| University of Kansas | Westwood | Kansas | 66205 | — |
| Albany Medical College | Albany | New York | 12208 | — |
| NYU Langone Health | New York | New York | 10016 | — |
| Great Lakes Physician PC d/b/a Western New York Urology Associates | Sanborn | New York | 14132 | — |
| Montefiore Medical Center | The Bronx | New York | 10461 | — |
| Levine Cancer Institute | Charlotte | North Carolina | 28204 | — |
| The Urology Group | Cincinnati | Ohio | 45212 | — |
| The Ohio State University- James Cancer Hospital | Columbus | Ohio | 43221 | — |
| Oregon Health And Science University | Portland | Oregon | 97239 | — |
| MidLantic Urology | Bala-Cynwyd | Pennsylvania | 19004 | — |
| University of Pittsburgh Medical Center - Cancer Centers | Pittsburgh | Pennsylvania | 15232 | — |
| Urology Associates | Nashville | Tennessee | 37209 | — |
| UT Southwestern Medical Center | Dallas | Texas | 75390 | — |
| University of Washington | Seattle | Washington | 98008 | — |
| Medical College of Wisconsin Froedtert Hospital | Milwaukee | Wisconsin | 53226 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 128 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT04172675, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Feb 24, 2026 · Synced Oct 22, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT04172675 live on ClinicalTrials.gov.